Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Flagship seeds Sigilon with $23.5mm to develop Type I diabetes therapy

Executive Summary

Flagship Pioneering launched Sigilon Therapeutics Inc. and seeded the company with $23.5mm. The start-up, armed with the research of its co-founders Daniel Anderson, PhD, and Robert Langer (both from MIT), is using an alginate-based polymeric capsule to encapsulate allogeneic cells that have been engineered into insulin-producing pancreatic beta cells. The company believes that its technology will avoid tissue scarring and immune responses that would other destroy implanted cells before they can be effective as a treatment for Type I diabetes.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies